Maigrot Jean-Luc A, Starling Randall C, Taimeh Ziad, Tong Michael Z Y, Soltesz Edward G, Weiss Aaron J
Department of Thoracic and Cardiovascular Surgery, Kaufman Center for Heart Failure Treatment and Recovery, Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio.
Department of Cardiovascular Medicine, Kaufman Center for Heart Failure Treatment and Recovery, Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio.
JTCVS Open. 2023 Oct 31;16:430-446. doi: 10.1016/j.xjon.2023.10.028. eCollection 2023 Dec.
The aim of this study was to explore the associations between percutaneous ventricular assist device (pVAD) insertion timing relative to cardiac surgery and patient outcomes.
The Nationwide Inpatient Sample was queried for patients undergoing cardiac surgery and pVAD insertion in the same admission from 2016 to 2019. Patients were stratified by timing of pVAD insertion. Preoperative characteristics, postoperative complications, and mortality were compared among groups.
Overall, 3695 patients underwent cardiac surgery and pVAD insertion during the same hospitalization (pre: 1130, intra: 1690, and post: 875). The distribution of cardiac surgery procedures was similar across groups. Median Elixhauser Comorbidity Index was 13 for pre-, 15 for intra-, and 17 for postoperative pVAD patients ( = .021). Patients who received a postoperative pVAD were associated with increased mortality (pre: 18%, intra: 39%, and post: 54%; < .01). Increased complication rates were also associated with postoperative pVAD insertion (pre: 61%, intra: 55%, and post: 75%; < .01). Preoperative pVAD insertion was associated with increase rates of sepsis (pre: 18%, intra: 9.8%, and post: 17%; = .01) and pneumonia (pre: 38%, intra: 23%, and post: 31%; < .01). Postoperative pVAD insertion was associated with increased rates of gastrointestinal bleeding (pre: 2.2%, intra: 3.0%, and post: 7.4%; = .01), renal failure (pre: 10%, intra: 9.2%, and post: 17%; = .01), and prolonged ventilation (pre: 44%, intra: 41%, and post: 54%; = .02).
Postoperative pVAD insertion following cardiac surgery was associated with increased complications and mortality compared with preoperative or intraoperative insertion. Further studies should explore optimal utilization and timing of pVAD insertion in patients undergoing cardiac surgery.
本研究旨在探讨经皮心室辅助装置(pVAD)相对于心脏手术的植入时机与患者预后之间的关联。
查询2016年至2019年在同一住院期间接受心脏手术和pVAD植入的患者的全国住院患者样本。根据pVAD植入时机对患者进行分层。比较各组的术前特征、术后并发症和死亡率。
总体而言,3695例患者在同一住院期间接受了心脏手术和pVAD植入(术前:1130例,术中:1690例,术后:875例)。各组心脏手术程序的分布相似。术前pVAD患者的埃利克斯豪泽合并症指数中位数为13,术中为15,术后为17(P = 0.021)。接受术后pVAD的患者死亡率增加(术前:18%,术中:39%,术后:54%;P < 0.01)。术后pVAD植入也与并发症发生率增加相关(术前:61%,术中:55%,术后:75%;P < 0.01)。术前pVAD植入与败血症发生率增加相关(术前:18%,术中:9.8%,术后:17%;P = 0.01)和肺炎发生率增加相关(术前:38%,术中:23%,术后:31%;P < 0.01)。术后pVAD植入与胃肠道出血发生率增加相关(术前:2.2%,术中:3.0%,术后:7.4%;P = 0.01)、肾衰竭发生率增加相关(术前:10%,术中:9.2%,术后:17%;P = 0.01)和通气时间延长相关(术前:44%,术中:41%,术后:54%;P = 0.02)。
与术前或术中植入相比,心脏手术后植入术后pVAD与并发症和死亡率增加相关。进一步的研究应探讨心脏手术患者pVAD植入的最佳利用和时机。